CD274 and neoplasm: Due to the disruption of immunological checkpoints in the tumor microenvironment, the alterations result in resistance to ICIs, particularly anti-PD-L1/PD-1 signaling inhibitors, which decrease T cell suppression and boost the antitumor immune response [42].